Treatment For Feline Leukemia (FeLV) And Immunodeficiency Virus (FIV) Receives License Renewal From USDA

T-Cyte Therapeutics, Inc. announced their conditional license renewal from the United States Department of Agriculture for Lymphocyte T-Cell Immunomodulator (LTCI). LTCI is the first and only approved treatment aid in the United States for cats infected with feline leukemia virus (FeLV) and immunodeficiency virus (FIV). LTCI is licensed and distributed by IMULAN BioTherapeutics; a US based veterinary immunobiology company. Conditional licenses are granted by the USDA for products which have passed safety and purity testing and where there is an emergency need or no other product available. LTCI is undergoing additional efficacy and potency studies.

More from

• VDS launches VetResolve to help practices meet new complaints handling requirements
• Ronda.vet links locum shifts to CPD rewards in UK veterinary first
• Cancellations have been damaging locum work for years but no-one was keeping count - now Ronda is
• Vet-founded charity looking to support talented youngsters
• Virbac Confirms Immediate UK Availability of Syvazul BTV 8 Vaccine for Livestock Protection